Publication | Open Access

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

UrologyOncologyGenitourinary CancerMedicineAbiraterone Versus PlaceboClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseasePharmacologyOverall Survival Results